Results 61 to 70 of about 6,610 (196)

Evaluating Analytic Approaches to Determining Respiratory Syncytial Virus Seasonality—United States, 2014–2024

Influenza and Other Respiratory Viruses, Volume 20, Issue 7, July 2026.
ABSTRACT Background Respiratory syncytial virus (RSV) is a major cause of hospitalizations among infants and older adults in the United States. Determining RSV seasonality, which varies geographically, is essential to the timely administration of prevention products.
Sophia Chkonia, Sarah Hamid, Erica Billig Rose, Amber Winn, Erin Anderson, Benjamin J. Silk   +5 more
wiley   +1 more source

Guideline for the Diagnosis and Management of Heritable IFNAR1 Deficiency in Oceania

Journal of Paediatrics and Child Health, Volume 62, Issue 7, Page 1113-1120, July 2026.
ABSTRACT Autosomal recessive interferon alpha and beta receptor subunit 1 (IFNAR1) deficiency is a rare and heritable inborn error of immunity (IEI) predisposing individuals to severe and life‐threatening viral infections. It is more common in people of Western Polynesian ancestry, with estimates of around one in six thousand live births affected, due ...
Cecilia Verryt, Paul Gray, Peter McNaughton, Jane Peake, Melanie Wong, George Aho, Emma Best, Maia Brewerton, Flora Lutui, Litara Esera Tulifau, Rebecca Qin, Satupa‘itea Viali, Petine White, Andrew Wood, See‐Tarn Woon, Theresa Cole, Alberto Pinzon Charry, Kuang‐Chih Hsiao   +17 more
wiley   +1 more source

Respiratory Syncytial Virus Under the Lens of Structure: From Prefusion Stabilization to Next‐Generation Immunotherapies

iNew Medicine, Volume 2, Issue 2, June 2026.
This illustration integrates key concepts covered in the review, including high‐risk populations, viral structure, host entry factors, the replication cycle, and licensed antibody‐based prevention strategies. ABSTRACT Respiratory syncytial virus (RSV) is a negative‐sense RNA virus belonging to the genus Orthopneumovirus within the family Pneumoviridae.
Zekai Cheng, Qianqian Wang, Jiachen Zhang, Sandra Chiu   +3 more
wiley   +1 more source

Impact of RSV Preventive Strategies on Hospitalizations for Bronchiolitis in Infants

Pediatric Pulmonology, Volume 61, Issue 6, June 2026.
ABSTRACT Introduction Respiratory syncytial virus (RSV) is the leading cause of bronchiolitis and hospitalization in infants. Since 2023, France has implemented two preventive strategies aimed at reducing RSV burden: long‐acting monoclonal antibody nirsevimab and RSV vaccine for pregnant women, the latter becoming available from September 2024.
Marine Tarizzo, Julie Mesinèle, Blandine Prevost, Sophie Denamur, Elora Peulier‐Maitre, Loïc Guillot, Nadia Nathan, Harriet Corvol   +7 more
wiley   +1 more source

RSV N-nanorings fused to palivizumab-targeted neutralizing epitope as a nanoparticle RSV vaccine

, 2017
Respiratory syncytial virus (RSV) is the leading cause of acute respiratory infections in children, yet no vaccine is available. The sole licensed preventive treatment against RSV is composed of a monoclonal neutralizing ...
Descamps, Delphyne, Deloizy, Charlotte, McLellan, Jason S., Rameix Welti, Marie-Anne, Fix, Jenna   +4 more
core   +2 more sources

Respiratory syncytial virus prophylaxis in preterm infants: a cost-effectiveness study from Turkey

The Turkish Journal of Pediatrics, 2012
The main aim of this study was to evaluate the cost-effectiveness of respiratory syncytial virus (RSV) prophylaxis with palivizumab in Turkey, by comparing hospitalization rates and costs as well as results of risk analyses in preterm infants who ...
Mehmet Yekta Oncel, Banu Mutlu, Sumru Kavurt, Ahmet Yağmur Baş, Nihal Demirel, Mesut Akyol, Omer Erdeve, Uğur Dilmen   +7 more
doaj  

Use of palivizumab is underestimated in the Swedish Prescribed Drug Register – implications for register-based drug studies

, 2014
Marie Linder,1 Camilla Byström,1 Helle Kieler,1 Gunnar Bergman,2 Ann Haerskjold3,4 1Centre for Pharmacoepidemiology, Department of Medicine, Karolinska Institutet, Solna, Stockholm, Sweden; 2Stockholm-Uppsala Department of Pediatric Cardiology ...
Linder M, Kieler H, Bergman G, Byström C, Haerskjold A   +4 more
core  

Respiratory Syncytial Virus-Neutralizing Monoclonal Antibodies Motavizumab and Palivizumab Inhibit Fusion

, 2010
Respiratory syncytial virus (RSV) is a major cause of virus-induced respiratory disease and hospitalization in infants. Palivizumab, an RSV-neutralizing monoclonal antibody, is used clinically to prevent serious RSV-related respiratory disease in high ...
Nancy D. Ulbrandt, Len Incognito, Xing Cheng, Kelly Huang, Herren Wu   +4 more
core   +1 more source

Comparative Effectiveness of Monoclonal Antibody Prophylaxis for Preventing Severe Respiratory Syncytial Virus Infection in Infants: A Network Meta-Analysis

Journal of Clinical Question
Introduction: Respiratory syncytial virus (RSV) is a leading cause of LRTI and hospitalization in infants and young children. Passive immunization with monoclonal antibodies represents a major strategy for RSV prevention.
Tetsuya Nosho, Yukiho Otsu, Miri Nomura, Yumeng Zhang   +3 more
doaj   +1 more source

Palivizumab prophylaxis of RSV infections in Bosnia and Herzegovina

Journal of Pediatric and Neonatal Individualized Medicine, 2016
Background: Palivizumab is indicated for respiratory syncytial virus (RSV) prophylaxis in high-risk children. Methods: Observational study, based on 4 sites in Bosnia and Herzegovina (B&H), with institutional reports of infants at high risk for RSV ...
Suada Heljic, Hajrija Maksic, Hidajeta Begic, Fahrija Skokic, Darinka Glamuzina, Tomica Bozic, Stojislav Konjevic, Veroslava Milosevic, Sabina Terzic   +8 more
doaj   +1 more source